Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) have been assigned an average rating of “Hold” from the eleven analysts that are covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and two have assigned a strong buy recommendation to the company.
Several research firms recently weighed in on ZLDPF. Zacks Research upgraded shares of Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Barclays cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Finally, Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th.
Read Our Latest Stock Analysis on ZLDPF
Zealand Pharma A/S Stock Performance
OTCMKTS:ZLDPF opened at $33.08 on Tuesday. The stock has a market cap of $2.37 billion, a P/E ratio of 5.62 and a beta of 0.95. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. The business’s 50-day moving average price is $42.78 and its two-hundred day moving average price is $48.83. Zealand Pharma A/S has a twelve month low of $33.08 and a twelve month high of $83.12.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. Its research is primarily directed toward metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs, often using innovative peptide structures and delivery approaches.
Zealand’s portfolio has included dasiglucagon, a glucagon analogue developed for the treatment of severe hypoglycemia.
Further Reading
- Five stocks we like better than Zealand Pharma A/S
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
